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Why is this study of clinical importance?
Small subcortical brain infarcts, commonly known as
lacunar strokes, constituteabout 25% of ischaemic
strokes. Aspirin is accepted as a standard antiplatelet
therapy in patients with lacunar infarcts. Dual
Antiplatelet therapy has been associated with
increased bleeding, although it has been shown to
reduce the risk of stroke among patients with atrial
fibrillation.
The SPS3 trial was a randomized, multicenter clinical
trial conducted in 82 clinical centers inNorth America,
Latin America, and Spain. It tested two randomized
interventions, in a 2-by-2 factorial design, in patients
with MRI-confirmed lacunar stroke: clopidogrel and
aspirin versus aspirin alone and two target levels of
systolic blood pressure (<130 mm Hg vs. 130 to 149
mm Hg). 
This trial was not pharmaceutically sponsored. It was
an investigator initiated trial. The final results of the
antiplatelet component of the trial have now been
published.
Who were the participants?
Between 2003 and 2011, a total of 3020 patients were
enrolled in the study: 1503 in the group treated with
aspirin plus placebo and 1517 in the group treated
with aspirin plus clopidogrel.
Patients were eligible for participation in the study if
they were 30 years of age or older, had undergone a
symptomatic lacunar stroke within the preceding 180
days, and did not have surgically amenable ipsilateral
carotid artery disease or cardioembolism. 
What was the intervention?
In accordance with the 2-by-2 factorial design of
the study, eligible patients underwent
simultaneous randomization to the antiplatelet
intervention (in which both patients and
practitioners were unaware of group assignments)
and to one of the two groups defined by target
levels for systolic blood pressure (<130 mm Hg vs.
130 to 149 mm Hg) (with patients and practitioners
aware of the group assignments).
All participants were given 325 mg of enteric-coated
aspirin daily and were randomly assigned to receive
75 mg of clopidogrel daily or a matching placebo,
with adherence measured by means of pill counts
performed at quarterly follow-up visits.
What are the results?
The participants had a mean age of 63 years, and
63% were men. After a mean follow-up of 3.4 years,
the risk of recurrent stroke was not significantly
reduced with aspirin and clopidogrel (dual
antiplatelet therapy) (2.5% per year) as compared
with aspirin alone ( 2.7% per year) (hazard ratio, 0.92;
95% confidence interval [CI], 0.72 to 1.16), nor was
the risk of recurrent ischaemic stroke (hazard ratio,
0.82; 95% CI, 0.63 to 1.09) or disabling or fatal stroke
(hazard ratio, 1.06; 95% CI, 0.69 to 1.64). The risk of
major haemorrhage was almost doubled with dual
antiplatelet therapy (105 haemorrhages, 2.1% per
year) as compared with aspirin alone (56, 1.1% per
year) (hazard ratio, 1.97; 95% CI, 1.41 to 2.71;
P<0.001). 
What were the conclusions?
Among patients with recent lacunar strokes, the
addition of clopidogrel to aspirin did not significantly
reduce the risk of recurrent stroke and did
significantly increase the risk of bleeding and death.
How does this impact us?
In Pakistan there is a high prevalence of Diabetes
mellitus and Hypertension which frequently causes
lacunar stroke. It appears from this trial, that at least
in Lacunar strokes, two agents (aspirin and
clopidrogel) are not better than one. In addition,
given the lifelong nature of therapy after stroke, this
data will assist in reducing prescription costs in a
resource poor nation. 
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